Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)
Who is this study for? Patients with ulcerative colitis
What treatments are being studied? Biopsies+Blood samples
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Procedure, Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patient with seropositive for CytoMegaloVirus (CMV) (IgG+)
• Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score \> 5 and an endoscopic subscore ≥ 2
• Social security affiliation
• Signed informed consent
Locations
Other Locations
France
HCL-Hôpital Lyon Sud
RECRUITING
Lyon
Chu Saint-Etienne
RECRUITING
Saint-etienne
Contact Information
Primary
Xavier ROBLIN, MD PhD
xavier.roblin@chu-st-etienne.fr
(0)477828119
Backup
Sylvie PILLET, PhD
sylvie.pillet@chu-st-etienne.fr
(0)477828315
Time Frame
Start Date: 2019-07-17
Estimated Completion Date: 2026-04
Participants
Target number of participants: 196
Treatments
Experimental: QuantiFERON Test
Patient with CytoMegaloVirus (CMV) infection will be included. They will have biopsies and blood samples, composite of QuantiFERON-CytoMegaloVirus (QF-CMV) assay.
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de Saint Etienne